Compare UL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UL | GILD |
|---|---|---|
| Founded | 1930 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0B | 155.9B |
| IPO Year | N/A | 1992 |
| Metric | UL | GILD |
|---|---|---|
| Price | $66.08 | $124.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $127.60 |
| AVG Volume (30 Days) | 2.8M | ★ 6.9M |
| Earning Date | 07-31-2025 | 02-10-2026 |
| Dividend Yield | ★ 3.43% | 2.53% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | 3.32 | ★ 6.42 |
| Revenue | ★ $70,194,950,090.00 | $29,087,000,000.00 |
| Revenue This Year | N/A | $3.63 |
| Revenue Next Year | N/A | $3.10 |
| P/E Ratio | $22.17 | ★ $19.42 |
| Revenue Growth | N/A | ★ 2.79 |
| 52 Week Low | $61.11 | $88.57 |
| 52 Week High | $73.87 | $128.70 |
| Indicator | UL | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 64.78 | 54.46 |
| Support Level | $64.95 | $118.17 |
| Resistance Level | $65.77 | $127.41 |
| Average True Range (ATR) | 0.84 | 2.85 |
| MACD | 0.29 | 0.36 |
| Stochastic Oscillator | 98.35 | 70.11 |
Unilever is a diversified beauty, wellbeing, and personal care (44% of 2024 sales by value), homecare (20%), and packaged food (36%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).